Tenderwize
Retour à la recherche

Open House Original Discount Agreements 2025-14 - Tiotropiumbromid/Olodaterol (Combination of Active Substances)

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 277 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-14 - Tiotropiumbromid/Olodaterol (Wirkstoffkombination)

50/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

The notice clarifies this is not a public procurement subject to procurement law, but an Open House. Legal recourse is...

No estimated value or volume provided; the actual demand under the agreement is unknown. Potential low uptake if other...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of Tiotropiumbromid/Olodaterol combination drug (COPD treatment).
  • Entering into a discount agreement (Rabattvertrag) under §130c SGB V with TK, HEK, and hkk.
Afficher le résumé complet

Open House (non-competitive) procedure by Techniker Krankenkasse and other insurers to conclude discount agreements for the drug combination Tiotropiumbromid/Olodaterol. Eligible pharmaceutical entrepreneurs can join at any time during the contract period (01.06.2025-31.05.2027). No estimated value provided. All eligible suppliers are accepted; no award criteria.

Risques

The notice clarifies this is not a public procurement subject to procurement law, but an Open House. Legal recourse is...

No estimated value or volume provided; the actual demand under the agreement is unknown. Potential low uptake if other...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Participant must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) under AMG §4(18) for the offered drug.
  • Must have a valid marketing authorization for the drug combination under AMG §21(1) or equivalent right to market.

Certifications

  • Must certify no exclusion grounds under GWB §§123-124 (self-declaration required).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Original Discount Agreements 2025-14 - Tiotropiumbromid/Olodaterol (Combination of Active Substances)

Setting up a discount agreement for the supply of Tiotropiumbromid/Olodaterol combination drug to TK and partner insurers. Open to all eligible pharmaceutical entrepreneurs during the contract period.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Date limite

Deadline May 30, 2027

Détails de la procédure

Date de publication
16 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
251794-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3